[EN] 1,1'-DIADAMANTYL CARBOXYLIC ACIDS, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE [FR] ACIDES 1,1'-DIADAMANTYL CARBOXYLIQUES, MÉDICAMENTS CONTENANT DE TELS COMPOSÉS ET APPLICATION ASSOCIÉE
[EN] 1,1'-DIADAMANTYL CARBOXYLIC ACIDS, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE [FR] ACIDES 1,1'-DIADAMANTYL CARBOXYLIQUES, MÉDICAMENTS CONTENANT DE TELS COMPOSÉS ET APPLICATION ASSOCIÉE
1,1'-Diadamantyl carboxylic acids, medicaments containing such compounds and their use
申请人:Eckhardt Matthias
公开号:US20110269736A1
公开(公告)日:2011-11-03
The present invention relates to compounds defined by formula (I) wherein the group R is defined as in claim
1
, possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11 β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases.
1,1′-diadamantyl carboxylic acids, medicaments containing such compounds and their use
申请人:Boehringer Ingelheim International GmbH
公开号:US08309597B2
公开(公告)日:2012-11-13
The present invention relates to compounds defined by formula (I) wherein the group R is defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases.
1,1'-DIADAMANTYL CARBOXYLIC ACIDS, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE
申请人:Boehringer Ingelheim International GmbH
公开号:EP2318355A1
公开(公告)日:2011-05-11
US8309597B2
申请人:——
公开号:US8309597B2
公开(公告)日:2012-11-13
[EN] 1,1'-DIADAMANTYL CARBOXYLIC ACIDS, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE<br/>[FR] ACIDES 1,1'-DIADAMANTYL CARBOXYLIQUES, MÉDICAMENTS CONTENANT DE TELS COMPOSÉS ET APPLICATION ASSOCIÉE
申请人:BOEHRINGER INGELHEIM INT
公开号:WO2010010174A1
公开(公告)日:2010-01-28
The present invention relates to compounds defined by formula (I) wherein the group R is defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11 β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases.